There is no single genetic blueprint for cancer. Instead, each individual cancer draws on a collection of acquired mutations that endow the cells with a selective advantage and superior immune evasion ...

Whole genome sequencing (WGS) provides comprehensive, individualised cancer genomic information. However, routine tumour biopsies are formalin-fixed and paraffin-embedded (FFPE), damaging DNA, ...

In cancer genome analysis, identifying pathogenic alterations and assessing their effects on oncogenic processes is important. Although whole exome sequencing (WES) can effectively detect such changes ...

Whole genome sequencing has improved clinical care of some children with cancer in England by informing individual patient care. New research from the Wellcome Sanger Institute, Cambridge University ...

It's a fundamental principle of science: Correlation does not equal causation. Every cancer cell has genetic mutations, but not all of those mutations necessarily drive the cancer. A Harvard Medical ...

A team of scientists from the Barbara Ann Karmanos Cancer Institute, Wayne State University and institutions across the U.S.

Researchers have long suspected that the gut microbiome—the community of bacteria and other microorganisms living in the ...

Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer therapy ...

Disparate Rates of Germline Variants in Cancer Predisposition Genes in African American/Black Compared With Non-Hispanic White Individuals Between 2015 and 2022 The funding sources did not play a role ...

PACB launched a joint FFPE workflow with Covaris to improve the sequencing of archived tumor samples. The solution enhances DNA recovery, boosting structural variant detection and mutation phasing ...

April 9 — An ambitious plan to sequence large numbers of cancer genomes is underway, under the auspices of the International Cancer Genome Consortium (ICGC). Although the proposal has already stirred ...

Real-world darolutamide safety and effectiveness in nonmetastatic castration-resistant prostate cancer (nmCRPC) by lipid-modifying agent use: Post hoc analyses of DAROL interim analysis 4 (IA4). This ...